Optimising Heart Disease Prevention And Management
Funder
National Health and Medical Research Council
Funding Amount
$4,647,175.00
Summary
As we become older and risk factors such as obesity become more common, our biggest contributor to death and disability, cardiovascular disease (including heart disease), will continue to exert an enormous burden on our health care system and society. We will extend our ground-breaking research on multidisciplinary teams to create new and innovative health care programs to optimise the prevention and management of new heart disease and chronic forms of heart disease.
TRIP Fellowship: Bridging The Evidence Practice Gap In Secondary Prevention In Stroke
Funder
National Health and Medical Research Council
Funding Amount
$146,247.00
Summary
Various medications have been shown to reduce the risk of recurrent vascular disease after stroke. This study aims to improve the frequency of use of these medications in patients discharged from hospital after a stroke.
An International Randomised Trial Of Low-dose Aspirin To Prevent Recurrent Venous Thromboembolism (INSPIRE)
Funder
National Health and Medical Research Council
Funding Amount
$1,989,986.00
Summary
Patients who develop venous blood clots or pulmonary embolism, without an underyling cause, are at very high risk of recurrence once anticoagulant treatment (warfarin) is discontinued. The international INSPIRE trial is assessing whether low-dose aspirin treatment (a simple and cheap alternative to warfarin) is effective and safe in preventing further blood clots. If proven effective, aspirin could potentially prevent thousands of patients worldwide from experiencing such events.
Low-dose Aspirin To Prevent Recurrent Venous Thromboembolism (ASPIRE) Study: A Multicentre Randomised Trial
Funder
National Health and Medical Research Council
Funding Amount
$1,108,600.00
Summary
In approximately one-third of patients who develop deep vein thrombosis or pulmonary embolism, this event is 'unprovoked' . These patients are at very high risk of recurrence once treatment with warfarin is discontinued. Warfarin treatment is very effective to prevent recurrence but is inconvenient because it has to be very closely monitored with blood tests and also causes serious bleeding complications in a significant number of patients. There are currently no other treatments available to pr ....In approximately one-third of patients who develop deep vein thrombosis or pulmonary embolism, this event is 'unprovoked' . These patients are at very high risk of recurrence once treatment with warfarin is discontinued. Warfarin treatment is very effective to prevent recurrence but is inconvenient because it has to be very closely monitored with blood tests and also causes serious bleeding complications in a significant number of patients. There are currently no other treatments available to prevent recurrent thrombosis. Low-dose aspirin treatment offers a simple, inexpensive, and widely practicable alternative to warfarin but has not yet been proven to be effective for preventing recurrent thrombosis. This study will investigate the effectiveness and safety of aspirin to prevent recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism who have completed standard anticoagulation with heparin and warfarin. If proven to be effective, aspirin could potentially prevent thousands of patients from experiencing recurrent venous thromboembolism or fatal pulmonary embolism worldwide and also save millions of dollars in health care costs each year.Read moreRead less
Alfred And Baker Medical Unit Centre For Clinical Cardiovascular Research
Funder
National Health and Medical Research Council
Funding Amount
$2,000,000.00
Summary
This Centre has three objectives: to create clinical research platforms; to provide time and training for advanced cardiology trainees, young clinical academics, research nurses, allied health staff and non-medical science graduates; and to translate previously established local and international research outcomes into knowledge, education and health benefits for the wider Australian community.
QUality Improvement In Primary Care To Prevent Hospitalisations And Improve Effectiveness And Efficiency Of Care For People Living With Heart Disease (QUEL)
Funder
National Health and Medical Research Council
Funding Amount
$828,305.00
Summary
Heart disease accounts for a great number of deaths and admissions to hospital. We aim to improve ongoing prevention for people with heart disease by supporting general practices to use their data and provide more systematic care. We propose a randomised trial to determine whether a practice level strategy reduces cardiovascular events and hospitalisations and saves money. The research will directly inform government decision-making and policy regarding primary care incentive payment programs.
Improving Health Outcomes In Atrial Fibrillation Via Optimal Management
Funder
National Health and Medical Research Council
Funding Amount
$314,644.00
Summary
Atrial fibrillation (AF; the most common irregular heart beat seen in medical practice) is becoming increasingly more common, costly and deadly in Australia and worldwide, particularly due to population ageing. The goal of this research is to develop 3 patient assessment tools focussing specifically on AF and improving a patient’s ability to care for themself. Overall, the goal is to make patient care more AF focussed and individual and more likely to result in better long-term health benefits.
Smartphone Based Secondary Prevention Program For Patients With Acute Coronary Syndromes: A Randomised Control Trial
Funder
National Health and Medical Research Council
Funding Amount
$122,714.00
Summary
Patients at the highest risk of premature death, heart attacks and re-hospitalization are those with known coronary heart disease. Secondary prevention strategies and cardiac rehabilitation are under-utilised in clinical practice. We aim to close this treatment gap by establishing the role of a smartphone based secondary prevention program in patients who have experienced a heart attack. Our innovative model of care may empower patients to optimise their cardiac health.
Cognitive Interventions For Older Adults At-risk Of Dementia And With Early-stage Neurodegenerative Disease
Funder
National Health and Medical Research Council
Funding Amount
$544,348.00
Summary
My postdoctoral research program focuses on secondary prevention for cognitive decline and early intervention for mild-stage dementia, by developing and evaluating cognitive interventions e.g. Cognitive Training, psychoeducation, adjunctive therapies and e-health. I am perfectly positioned for this research, with an established track record in aging, ideal research environment, excellent supervision/collaborative opportunities, and unique background of both research and clinical training.
Secondary Prevention – Increasing Uptake And Engagement To Reduce Cardiovascular Events
Funder
National Health and Medical Research Council
Funding Amount
$421,747.00
Summary
Cardiovascular disease is a common and long-term health problem. Dr Redfern will continue to develop new and existing strategies for increasing uptake of and adherence to long-term behavioural change by people living with heart disease. The work will encompass policy development and media campaigns as well as trialling electronic communication systems such as text messaging and smart phone applications and new approaches including providing incentives for people who enact healthy behaviours.